Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 962: 176251, 2024 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-38061471

RESUMO

Alzheimer's disease (AD) is the most common neurodegenerative disease. The morbidity of Alzheimer's disease is currently on the rise worldwide, but no effective treatment is available. Cornus officinalis is an herb and edible plant used in traditional Chinese medicine, whose extract has neuroprotective properties. In this investigation, we endeavored to refine a systems pharmacology strategy combining bioinformatics analysis, drug prediction, network pharmacology, and molecular docking to screen tetrahydroalstonine (THA) from Cornus officinalis as a therapeutic component for AD. Subsequent in vitro experiments were validated using MTT assay, Annexin V-PI flow cytometry, Western blotting, and immunofluorescence analysis. In Palmitate acid-induced SK-N-MC cells, THA restored the impaired PI3K/AKT signaling pathway, regulated insulin resistance, and attenuated BACE1 and GSK3ß activity. In addition, THA significantly reduced cell apoptosis rate, down-regulated relative levels of p-JNK/JNK, Bax/Bcl-2, cytochrome C, active caspase-3 and caspase-3, and attenuated Palmitate acid-induced Aß1-42 and Tau generation. THA may regulate the phenotype of AD and reduce cell apoptosis by modulating the PI3K/AKT signaling pathway. This systematic analysis provides new ramifications concerning the therapeutic utility of tetrahydroalstonine for AD.


Assuntos
Doença de Alzheimer , Doenças Neurodegenerativas , Humanos , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/genética , Proteínas Proto-Oncogênicas c-akt/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Ácido Palmítico/toxicidade , Secretases da Proteína Precursora do Amiloide/metabolismo , Caspase 3/metabolismo , Peptídeos beta-Amiloides/metabolismo , Simulação de Acoplamento Molecular , Ácido Aspártico Endopeptidases/metabolismo , Ácido Aspártico Endopeptidases/farmacologia , Ácido Aspártico Endopeptidases/uso terapêutico , Transdução de Sinais , Palmitatos/farmacologia
2.
Cell Mol Neurobiol ; 43(7): 3465-3478, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37378849

RESUMO

Leptin (LEP) can cross the blood-brain barrier and facilitate cross-talk between the adipose tissue and central nerve system (CNS). This study aimed to investigate the effect of 8-week high-intensity interval training (HIIT) on the LEP signaling in the hippocampus of rats with type 2 diabetes. 20 rats were randomly divided into four groups: (i) control (Con), (ii) type 2 diabetes (T2D), (iii) exercise (EX), and (iv) type 2 diabetes + exercise (T2D + EX). The rats in the T2D and T2D + EX were fed a high-fat diet for two months, then a single dose of STZ (35 mg/kg) was injected to induce diabetes. The EX and T2D + EX groups performed 4-10 intervals of treadmill running at 80-100% of Vmax. Serum and hippocampal levels of LEP as well as hippocampal levels of LEP receptors (LEP-R), Janus kinase 2 (JAK-2), signal transducer and activator of transcription 3 (STAT-3), activated protein kinase (AMP-K), proxy zoster receptor α (PGC-1α), beta-secretase 1 (BACE1), Beta-Amyloid (Aß), Phosphoinositide 3-kinases (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR), Glycogen Synthase Kinase 3 Beta (GSK3ß), and hyperphosphorylated tau proteins (TAU) were measured. One-way ONOVA and Tukey post-hoc tests were used to analyze the data. Serum and hippocampal levels of LEP as well as hippocampal levels of LEP-R, JAK-2, STAT-3, AMP-K, PGC1α, PI3K, AKT, and mTOR were increased while hippocampal levels of BACE1, GSK3B, TAU, and Aß were decreased in T2D + EX compared with T2D group. Serum LEP and hippocampal levels of LEP, LEP-R, JAK-2, STAT-3, AMP-K, PGC1α, PI3K, AKT, and mTOR were decreased. Conversely hippocampal levels of BACE1, GSK3B, TAU, and Aß were increased in T2D group compared with CON group. HIIT could improve LEP signaling in the hippocampus of rats with type 2 diabetes and decrease the accumulation of Tau and Aß, which may reduce the risk of memory impairments.


Assuntos
Diabetes Mellitus Tipo 2 , Treinamento Intervalado de Alta Intensidade , Ratos , Animais , Proteínas Proto-Oncogênicas c-akt/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Peptídeos beta-Amiloides/metabolismo , Secretases da Proteína Precursora do Amiloide/metabolismo , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/metabolismo , Leptina/metabolismo , Leptina/farmacologia , Ácido Aspártico Endopeptidases/metabolismo , Ácido Aspártico Endopeptidases/farmacologia , Proteínas tau/metabolismo , Hipocampo/metabolismo , Serina-Treonina Quinases TOR/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Mamíferos/metabolismo
3.
Naunyn Schmiedebergs Arch Pharmacol ; 396(9): 1931-1942, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-36864348

RESUMO

This study aimed to demonstrate the potential benefits of donepezil (DPZ) and vitamin D (Vit D) in combination to counteract the neurodegenerative disorders induced by CuSO4 intake in experimental rats. Neurodegeneration (Alzheimer-like) was induced in twenty-four male Wistar albino rats by CuSO4 supplement to drinking water (10 mg/L) for 14 weeks. AD rats were divided into four groups: untreated AD group (Cu-AD) and three treated AD groups; orally treated for 4 weeks with either DPZ (10 mg/kg/day), Vit D (500 IU/kg/day), or DPZ + Vit D starting from the 10th week of CuSO4 intake. Another six rats were used as normal control (NC) group. The hippocampal tissue content of ß-amyloid precursor protein cleaving enzyme 1 (BACE1), phosphorylated Tau (p-tau), clusterin (CLU), tumor necrosis factor-α (TNF-α), caspase-9 (CAS-9), Bax, and Bcl-2 and the cortical content of acetylcholine (Ach), acetylcholinesterase (AChE), total antioxidant capacity (TAC), and malondialdehyde (MDA) were measured. Cognitive function tests (Y-maze) and histopathology studies (hematoxylin and eosin and Congo red stains) and immunohistochemistry for neurofilament. Vit D supplementation alleviated CuSO4-induced memory deficits including significant reduction hippocampal BACE1, p-tau, CLU, CAS-9, Bax, and TNF-α and cortical AChE and MDA. Vit D remarkably increased cortical Ach, TAC, and hippocampal Bcl-2. It also improved neurobehavioral and histological abnormalities. The effects attained by Vit D treatment were better than those attained by DPZ. Furthermore, Vit D boosted the therapeutic potential of DPZ in almost all AD associated behavioral and pathological changes. Vit D is suggested as a potential therapy to retard neurodegeneration.


Assuntos
Doença de Alzheimer , Lesões Encefálicas , Disfunção Cognitiva , Ratos , Masculino , Animais , Donepezila/efeitos adversos , Cobre , Sulfato de Cobre/efeitos adversos , Sulfato de Cobre/metabolismo , Doença de Alzheimer/induzido quimicamente , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/metabolismo , Secretases da Proteína Precursora do Amiloide/metabolismo , Secretases da Proteína Precursora do Amiloide/farmacologia , Secretases da Proteína Precursora do Amiloide/uso terapêutico , Vitamina D/farmacologia , Vitamina D/uso terapêutico , Acetilcolinesterase/metabolismo , Sulfatos/metabolismo , Sulfatos/farmacologia , Sulfatos/uso terapêutico , Proteína X Associada a bcl-2/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Ratos Wistar , Ácido Aspártico Endopeptidases/metabolismo , Ácido Aspártico Endopeptidases/farmacologia , Ácido Aspártico Endopeptidases/uso terapêutico , Lesões Encefálicas/metabolismo , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Antioxidantes/metabolismo , Vitaminas/farmacologia , Encéfalo , Disfunção Cognitiva/induzido quimicamente
4.
Rejuvenation Res ; 26(2): 57-67, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-36734410

RESUMO

Ischemia stroke is thought to be one of the vascular risks associated with neurodegenerative diseases, such as Alzheimer's disease (AD). Hydroxysafflor yellow A (HSYA) has been reported to protect against stroke and AD, while the underlying mechanism remains unclear. In this study, SH-SY5Y cell model treated with oxygen-glucose deprivation/reperfusion (OGD/R) was used to explore the potential mechanism of HSYA. Results from cell counting kit-8 (CCK-8) showed that 10 µM HSYA restored the cell viability after OGD 2 hours/R 24 hours. HSYA reduced the levels of malondialdehyde and reactive oxygen species, while improved the levels of superoxide dismutase and glutathione peroxidase. Furthermore, apoptosis was inhibited, and the expression of brain-derived neurotrophic factor was improved after HSYA treatment. In addition, the expression levels of amyloid-ß peptides (Aß) and BACE1 were decreased by HSYA, as well as the expression levels of binding immunoglobulin heavy chain protein, PKR-like endoplasmic reticulum (ER) kinase pathway, and activating transcription factor 6 pathway, whereas the expression level of protein disulfide isomerase was increased. Based on these results, HSYA might reduce Aß toxicity after OGD/R by interfering with apoptosis, oxidation, and neurotrophic factors, as well as relieving ER stress.


Assuntos
Chalcona , Neuroblastoma , Fármacos Neuroprotetores , Traumatismo por Reperfusão , Acidente Vascular Cerebral , Humanos , Oxigênio/metabolismo , Fármacos Neuroprotetores/farmacologia , Secretases da Proteína Precursora do Amiloide/farmacologia , Glucose/metabolismo , Ácido Aspártico Endopeptidases/farmacologia , Quinonas/farmacologia , Apoptose , Chalcona/farmacologia , Traumatismo por Reperfusão/metabolismo , Reperfusão , Estresse do Retículo Endoplasmático
5.
Bioengineered ; 13(4): 10889-10901, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35481549

RESUMO

This study aimed to analyze the function and latent mechanism of long noncoding RNA BACE1-antisense transcript (lncRNA BACE1-AS) in MPP+-induced SH-SY5Y cells. SH-SY5Y cells were cultivated in 1 mM MPP+ for 24 h to establish Parkinson's disease (PD) model in vitro. TargetScan and luciferase reporter assay were conducted to predict and verify the interaction between microRNA (miR)-214-3p and CDIP1 (Cell death-inducing p53-target protein 1). Cell viability, lactate dehydrogenase (LDH) release, and cell apoptosis were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide (MTT), LDH, and flow cytometer. The secretion of inflammatory factors and representative biomarkers of oxidative stress, including reactive oxygen species (ROS) and superoxide dismutase (SOD) were assessed using enzyme-linked immunosorbent assay (ELISA) and specific assay kits. Results suggested that lncRNA BACE1-AS was over-expressed and miR-214-3p was under-expressed in MPP+-stimulated SH-SY5Y cells. Further analyses revealed that MPP+ inhibited cell viability; enhanced cell apoptosis, Cleaved Caspase-3 expression and Cleaved Caspase-3/GAPDH ratio; induced oxidative stress and inflammation in SH-SY5Y cells were inhibited by lncRNA BACE1-AS-siRNA transfection; and all these inhibitions were reversed by miR-214-3p inhibitor. In addition, we found that CDIP1 was directly targeted by miR-214-3p and up-regulated in MPP+-stimulated SH-SY5Y cells. Further functional assays suggested that CDIP1-plasmid reversed the effects of miR-214-3p mimic on MPP+-stimulated SH-SY5Y cells. In conclusion, lncRNA BACE1-AS regulates SH-SY5Y cell proliferation, apoptosis, inflammatory response, and oxidative stress through direct regulation of miR-214-3p/CDIP1 signaling axis, and could be a potential candidate associated with the diagnosis and treatment of PD.


Assuntos
MicroRNAs , Doença de Parkinson , RNA Longo não Codificante , 1-Metil-4-fenilpiridínio/farmacologia , Secretases da Proteína Precursora do Amiloide/genética , Secretases da Proteína Precursora do Amiloide/metabolismo , Secretases da Proteína Precursora do Amiloide/farmacologia , Apoptose/genética , Ácido Aspártico Endopeptidases/genética , Ácido Aspártico Endopeptidases/metabolismo , Ácido Aspártico Endopeptidases/farmacologia , Caspase 3/metabolismo , Linhagem Celular Tumoral , Humanos , MicroRNAs/metabolismo , Doença de Parkinson/genética , Doença de Parkinson/metabolismo , RNA Longo não Codificante/metabolismo , Proteína Supressora de Tumor p53
6.
Biol Chem ; 396(12): 1369-75, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26351912

RESUMO

Ten secreted aspartic proteases (Saps) of Candida albicans cleave numerous peptides and proteins in the host organism and deregulate its homeostasis. Human kininogens contain two internal antimicrobial peptide sequences, designated NAT26 and HKH20. In our current study, we characterized a Sap-catalyzed cleavage of kininogen-derived antimicrobial peptides that results in the loss of the anticandidal activity of these peptides. The NAT26 peptide was effectively inactivated by all Saps, except Sap10, whereas HKH20 was completely degraded only by Sap9. Proteolytic deactivation of the antifungal potential of human kininogens can help the pathogens to modulate or evade the innate immunity of the host.


Assuntos
Peptídeos Catiônicos Antimicrobianos/antagonistas & inibidores , Ácido Aspártico Endopeptidases/farmacologia , Candida albicans/enzimologia , Interações Hospedeiro-Patógeno , Cininogênios/metabolismo , Sequência de Aminoácidos , Ácido Aspártico Endopeptidases/metabolismo , Cromatografia Líquida , Humanos , Cininogênios/antagonistas & inibidores , Cininogênios/química , Dados de Sequência Molecular
7.
PLoS One ; 8(5): e64105, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23734186

RESUMO

BACKGROUND: The innate pattern recognition C-type-lectin receptors (CLRs), including mannose receptor (MRC1; CD206), have been suggested to functionally interact with allergens and are critical in controlling immune response. Fibrocytes have been considered to play a role in allergic asthma. Here we sought to investigate the functional interaction of cockroach allergens with CD206 in fibrocytes. METHODS: Profiling of N-linked glycans from natural purified cockroach allergen Bla g 2 was accomplished by MALDI-MS. The binding activity of cockroach allergens to CD206 was determined by solid-phase binding assays. Levels of CD206 expression on human fibrocytes and CD206 mediated signaling and cytokine production in Bla g 2 treated fibrocytes were determined. RESULTS: Profiling of N-linked glycans from Bla g 2 revealed a predominance of small, mannose-terminated glycans with and without fucose. Significant binding of Bla g 2 to CD206 was observed, which was inhibited by yeast mannan (a known CD206 ligand), free mannose, and a blocking antibody (anti-hMR). Flow cytometric analyses of human fibrocytes (CD45(+) and collagen-1(+)) showed selective expression of CD206 on fibrocytes. Functionally, a concentration-dependent uptake of FITC labeled Bla g 2 by fibrocytes was observed, but was significantly inhibited by anti-hMR. Bla g 2 can stimulate up-regulation of inflammatory cytokines including TNF-alpha and IL-6 and activation of nuclear factor kappa B (NF-kB/p65), p38 mitogen-activated protein kinase (p38), ERK, and JNK in cultured fibrocytes. This increased secretion of TNF-alpha and IL-6 and activation of NF-kB, ERK, and JNK was significantly inhibited by the addition of either mannan or mannose. Furthermore, Bla g 2 induced increase in TNF-alpha and IL-6 production was also inhibited by the use of NF-kB, ERK, and JNK inhibitors. CONCLUSION: These results provide evidence supporting the existence of a functional cockroach allergen-CD206 axis in human fibrocytes, suggesting a role for CD206 in regulating allergen induced allergic responses in asthma.


Assuntos
Alérgenos/imunologia , Baratas/imunologia , Lectinas Tipo C/imunologia , Lectinas de Ligação a Manose/imunologia , Células-Tronco Mesenquimais/imunologia , Receptores de Superfície Celular/imunologia , Alérgenos/metabolismo , Alérgenos/farmacologia , Animais , Ácido Aspártico Endopeptidases/imunologia , Ácido Aspártico Endopeptidases/metabolismo , Ácido Aspártico Endopeptidases/farmacologia , Western Blotting , Células Cultivadas , Baratas/metabolismo , Citocinas/imunologia , Citocinas/metabolismo , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Humanos , Lectinas Tipo C/metabolismo , Mananas/metabolismo , Mananas/farmacologia , Manose/metabolismo , Manose/farmacologia , Receptor de Manose , Lectinas de Ligação a Manose/metabolismo , Células-Tronco Mesenquimais/efeitos dos fármacos , Células-Tronco Mesenquimais/metabolismo , Proteínas Quinases Ativadas por Mitógeno/imunologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Polissacarídeos/imunologia , Polissacarídeos/metabolismo , Ligação Proteica/efeitos dos fármacos , Ligação Proteica/imunologia , Receptores de Superfície Celular/metabolismo , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz , Fator de Transcrição RelA/imunologia , Fator de Transcrição RelA/metabolismo
8.
Oral Oncol ; 47(9): 847-54, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21763177

RESUMO

The HIV/SIV accessory protein Nef is known to down-modulate cell surface receptors that are required for virus entry such as CD4, CCR5 and CXCR4 to block lethal viral superinfection of the infected cell. The chemokine receptor CXCR4 also plays an important role in promoting cell proliferation, metastasis and tumor angiogenesis. Therefore it was of interest to evaluate if Nef can down-regulate CXCR4 in tumor cells since this could affect these critical prognostic parameters. The CXCR4-expressing cell line ACC3 that was derived from a salivary gland adenoid cystic carcinoma (ACC) of the head and neck was transfected with Nef from SIV(mac239) and cell surface expression of the receptor was monitored by FACS analysis. Real time proliferation of cells was measured with the xCELLigence system (Roche, Mannheim, Germany). Cell migration was detected by an in vitro scratch assay. Similarly, COS-7 cells were co-transfected with CXCR4 and Nef and were treated as described for ACC3. In vitro tube formation was deployed to assess the effect of Nef on angiogenesis. siRNA was used for CXCR4 knockdown. Cell surface down-modulation of endogenous CXCR4 could be observed in ACC3 cells after Nef-transfection as well as in COS-7 cells after co-transfection of CXCR4 and Nef. Proliferation as well as migration of Nef-transfected ACC3 tumor cells appeared significantly reduced. In vitro tube formation was significantly lowered after Nef-transfection or CXCR4 knockdown with siRNA. SIV-Nef could serve as an interesting tool to study the biologic behavior of CXCR4-expressing tumors such as ACC. Deploying SIV-Nef thereby could help in the discovery of new therapeutic approaches for the treatment of ACC and other CXCR4-expressing tumors.


Assuntos
Ácido Aspártico Endopeptidases/farmacologia , Carcinoma Adenoide Cístico/metabolismo , Receptores CXCR4/metabolismo , Neoplasias das Glândulas Salivares/metabolismo , Proteínas Virais Reguladoras e Acessórias/fisiologia , Animais , Células COS/metabolismo , Linhagem Celular Tumoral , Movimento Celular , Proliferação de Células , Chlorocebus aethiops , Regulação para Baixo , Humanos , Técnicas In Vitro , Neovascularização Patológica , RNA Interferente Pequeno , Transfecção
9.
Peptides ; 31(10): 1926-33, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20600419

RESUMO

Endothelin-converting enzyme (ECE), a key peptidase in the endothelin (ET) system, cleaves inactive big ET-1 to produce active ET-1, which binds to ET(A) receptors to exert its vasoconstrictor and pressor effects. ECE inhibition could be beneficial in the treatment of hypertension. In this study, a set of eight lactoferricin B (LfcinB)-derived peptides, previously characterized in our laboratory as angiotensin-converting enzyme (ACE) inhibitory peptides, was examined for their inhibitory effects on ECE. In vitro inhibitory effects on ECE activity were assessed using both the synthetic fluorogenic peptide substrate V (FPS V) and the natural substrate big ET-1. To study vasoactive effects, an ex vivo functional assay was developed using isolated rabbit carotid artery segments. With FPS V, only four LfcinB-derived peptides induced inhibition of ECE activity, whereas the eight peptides showed ECE inhibitory effects with big ET-1 as substrate. Regarding the ex vivo assays, six LfcinB-derived peptides showed inhibition of big ET-1-induced, ECE-dependent vasoconstriction. A positive correlation between the inhibitory effects of LfcinB-derived peptides on ECE activity when using big ET-1 and the inhibitory effects on ECE-dependent vasoconstriction was shown. ECE-independent vasoconstriction induced by ET-1 was not affected, thus discarding effects of LfcinB-derived peptides on ET(A) receptors or intracellular signal transduction mechanisms. In conclusion, a combined in vitro and ex vivo method to assess the effects of potentially antihypertensive peptides on the ET system has been developed and applied to show the inhibitory effects on ECE-dependent vasoconstriction of six LfcinB-derived peptides, five of which were dual vasopeptidase (ACE/ECE) inhibitors.


Assuntos
Ácido Aspártico Endopeptidases/farmacologia , Hipertensão/fisiopatologia , Lactoferrina/farmacologia , Metaloendopeptidases/farmacologia , Peptídeos , Vasoconstrição/efeitos dos fármacos , Animais , Ácido Aspártico Endopeptidases/metabolismo , Endotelina-1/metabolismo , Enzimas Conversoras de Endotelina , Humanos , Lactoferrina/genética , Lactoferrina/metabolismo , Masculino , Metaloendopeptidases/metabolismo , Peptídeos/genética , Peptídeos/metabolismo , Peptídeos/farmacologia , Coelhos , Receptor de Endotelina A/metabolismo , Transdução de Sinais/fisiologia , Vasoconstrição/fisiologia
10.
Exp Biol Med (Maywood) ; 231(6): 824-9, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16741006

RESUMO

CGS 35601 is a triple vasopeptidase inhibitor (VPI) of angiotensin converting enzyme (ACE), neutral endopeptidase (NEP), and endothelin (ET) converting enzyme-1 (ECE-1), with respective IC(50) values of 22, 2, and 55 nM. The aim of the present study was to establish the hemodynamic profile of Zucker diabetic fatty (Zdf)-Fatty rats, a high-fat diet gene-prone model developing spontaneous Type 2 diabetes (T2D) and the effects of CGS 35601. Male Zdf-Fatty (14 weeks, n = 17-23), Zdf-Lean (14 weeks, n = 8-10), and Wistar (14 weeks, n = 9-10) rats on distinct diets were implanted with a catheter in the left carotid and placed individually in a metabolic cage for 30 days. The hemodynamic profile and some metabolic biomarkers were assessed daily. After a 7-day stabilization period, the Zdf-Fatty rats were divided into two groups: Group 1, controls (n = 7-10) receiving vehicle-saline (250 microl/hr) and Group 2, (n = 10-13) receiving increasing doses of CGS 35601 (0.1, 1, and 5 mg/kg/day x 6 days each, intra-arterially) followed by a 5-day washout period. Mean arterial blood pressure (MABP) of young Zdf-Fatty rats was compared with age-matched Zdf-Lean and Wistar rats, which were found similar. MABP decreased by 5.9% (from baseline at 102 +/- 5 to 96 +/- 4 mmHg), 12.7% (to 89 +/- 6 mmHg) and 21.6% (to 80 +/- 4 mmHg), at 0.1, 1, and 5 mg/kg/day, respectively, in CGS 35601-treated Zdf-Fatty rats. Systolic and diastolic blood pressures were similarly reduced. The heart rate was not affected. Hyperglycemic status and insulin-resistance were not modulated by short-term treatment. CGS 35601 presented an excellent short-term safety profile. This novel molecule and class of VPI may be of interest for lowering vascular tone. Further long-term studies, once cardiovascular and renal complications have developed in this T2D rat model are warranted to define the efficacy of this class of VPI.


Assuntos
Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/metabolismo , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/farmacologia , Animais , Ácido Aspártico Endopeptidases/administração & dosagem , Ácido Aspártico Endopeptidases/farmacologia , Combinação de Medicamentos , Enzimas Conversoras de Endotelina , Indóis/administração & dosagem , Indóis/agonistas , Masculino , Metaloendopeptidases/administração & dosagem , Metaloendopeptidases/farmacologia , Neprilisina/administração & dosagem , Neprilisina/farmacologia , Peptidil Dipeptidase A/administração & dosagem , Peptidil Dipeptidase A/farmacologia , Ratos , Ratos Wistar , Ratos Zucker
11.
Exp Biol Med (Maywood) ; 231(6): 830-3, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16741007

RESUMO

We previously reported that CGS 35601, a potent triple inhibitor of angiotensin-converting enzyme, neutral endopeptidase, and endothelin-converting enzyme 1, completely normalized mean arterial blood pressure (MABP) in 36-week-old spontaneously hypertensive rats, a normal renin model. The aim of the present study was to determine the effects of this triple vasopeptidase inhibitor (VPI) on the hemodynamic profile of instrumented, conscious, and unrestrained Dahl salt-sensitive (DSS) rats, a gene-prone, high-salt diet-induced low-renin hypertension model. Male DSS rats (mean weight [+/-SEM], 385 +/- 10 g) were fed a normal diet (Group 1) or a high-salt diet (Groups 2 and 3; 8% NaCl in food) for 6 weeks and then instrumented with a carotid catheter and placed individually in metabolic cages for 30 days. The hemodynamic, hematological, and biochemical profiles were assessed daily. Dose-dependent treatment started after a 7-day stabilization period in Groups 1 and 2 (vehicle dosage, 250 microl/hr) and Group 3 (CGS 35601 dosages of 0.1, 1, and 5 mg/kg/day for 6 days per dose by means of constant intra-arterial infusion), followed by a 5-day washout period. Two additional groups included normotensive Wistar rats (Group 4) and DSS rats that received a double high-salt solid (8% NaCl) and liquid (1% NaCl) diet (Group 5). The MABP in rats receiving CGS 35601 decreased in a dose-dependent fashion toward the baseline level observed in DSS rats receiving a normal diet. The heart rate was unaffected. The hemodynamic profile returned to normal during the washout period. This novel triple VPI is a potent and effective antihypertensive agent with a safe short-term profile that may be of interest for treating hypertension and other cardiovascular diseases. Other hypertensive rat models are being tested.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/farmacologia , Renina/sangue , Sódio na Dieta/farmacologia , Animais , Ácido Aspártico Endopeptidases/administração & dosagem , Ácido Aspártico Endopeptidases/farmacologia , Combinação de Medicamentos , Enzimas Conversoras de Endotelina , Masculino , Metaloendopeptidases/administração & dosagem , Metaloendopeptidases/farmacologia , Neprilisina/administração & dosagem , Neprilisina/farmacologia , Peptidil Dipeptidase A/administração & dosagem , Peptidil Dipeptidase A/farmacologia , Ratos , Ratos Endogâmicos Dahl
12.
Mol Biochem Parasitol ; 144(2): 167-76, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16183150

RESUMO

A Plasmodium falciparum gene closely linked to the chloroquine resistance locus encodes PfCG2, a predicted 320-330kDa protein. In the parasitized erythrocyte, PfCG2 expression rises sharply in the trophozoite stage and is detected in electron-dense patches along the parasitophorous vacuolar membrane (PVM), in the cytoplasm and in the digestive vacuole (DV). Results of extraction and partitioning experiments show that PfCG2 is a peripheral membrane protein. Exposure of trophozoite-infected erythrocytes to trypsin-containing buffer after streptolysin O permeabilization indicates that PfCG2 is exposed to the erythrocyte cytosol at the outer face of the PVM. PfCG2 is highly susceptible to hydrolysis by aspartic and cysteine proteases and shows dose-dependent accumulation in the presence of protease inhibitors. These results suggest that PfCG2 is delivered from the outside face of the PVM to the DV, where it is broken down by parasite proteases. PfCG2 interacts with erythrocyte cytoplasm and may be associated with processes of hemoglobin uptake and digestion by erythrocytic-stage parasites.


Assuntos
Hemoglobinas/metabolismo , Plasmodium falciparum/metabolismo , Proteínas de Protozoários/metabolismo , Animais , Ácido Aspártico Endopeptidases/farmacologia , Membrana Celular/metabolismo , Cisteína Endopeptidases/farmacologia , Citosol/metabolismo , Resistência a Medicamentos , Eritrócitos/química , Eritrócitos/citologia , Eritrócitos/parasitologia , Humanos , Estágios do Ciclo de Vida , Microscopia Eletrônica , Plasmodium falciparum/crescimento & desenvolvimento , Proteínas de Protozoários/efeitos dos fármacos , Vacúolos/metabolismo
13.
J Neurochem ; 94(2): 425-39, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15998293

RESUMO

The specific roles of syntaxin 5 (Syx 5) in the interaction with presenilin (PS) and the accumulation of beta-amyloid precursor protein (betaAPP), as well as the secretion of beta-amyloid peptide (Abeta peptide) were examined in NG108-15 cells. Syx 5, which localizes from the endoplasmic reticulum (ER) to the Golgi, bound to PS holoproteins, while the other Syxs studied did not. Among familial Alzheimer's disease (FAD)-linked PS mutants, PS1deltaE9, which lacks the endoproteolytic cleavage site, showed markedly decreased binding to Syx 5. The interaction domains in Syx 5 were mapped to the transmembrane region and to the cytoplasmic region containing the alpha-helical domains, which are distinct from the H3 (SNARE motif). Among all of the Syxs examined, only overexpression of Syx 5 resulted in the accumulation of betaAPP in the ER to cis-Golgi compartment, an attenuation of the amount of the C-terminal fragment (APP-CTF) of betaAPP, and a reduction in the secretion of Abeta peptides. Furthermore, co-expression of Syx 5 with C99 resulted in an increase in APP-CTF and suppressed Abeta secretion. Taken together, these results indicate that Syx 5 may play a specific role in the modulation of processing and/or trafficking of FAD-related proteins in neuronal cells by interaction with PS holoproteins in the early secretory compartment of neuronal cells.


Assuntos
Precursor de Proteína beta-Amiloide/metabolismo , Proteínas de Membrana/metabolismo , Neurônios/metabolismo , Secretases da Proteína Precursora do Amiloide , Animais , Ácido Aspártico Endopeptidases/farmacologia , Western Blotting/métodos , Células COS , Compartimento Celular , Chlorocebus aethiops , Cricetinae , Interações Medicamentosas , Endopeptidases , Ensaio de Imunoadsorção Enzimática/métodos , Imuno-Histoquímica/métodos , Imunoprecipitação/métodos , Proteínas de Membrana/classificação , Proteínas de Membrana/farmacologia , Camundongos , Mutagênese/fisiologia , Mutação/fisiologia , Neuroblastoma , Neurônios/efeitos dos fármacos , Biossíntese Peptídica/fisiologia , Fragmentos de Peptídeos/metabolismo , Fragmentos de Peptídeos/farmacologia , Plasmídeos/fisiologia , Presenilina-1 , Estrutura Terciária de Proteína/fisiologia , Proteínas Qa-SNARE , Proteínas Recombinantes de Fusão/metabolismo , Transfecção/métodos , Triglicerídeos/farmacologia , Ácido gama-Aminobutírico/análogos & derivados , Ácido gama-Aminobutírico/farmacologia
14.
Neuron ; 46(6): 849-55, 2005 Jun 16.
Artigo em Inglês | MEDLINE | ID: mdl-15953414

RESUMO

The three known inhibitors of axonal regeneration present in myelin--MAG, Nogo, and OMgp--all interact with the same receptor complex to effect inhibition via protein kinase C (PKC)-dependent activation of the small GTPase Rho. The transducing component of this receptor complex is the p75 neurotrophin receptor. Here we show that MAG binding to cerebellar neurons induces alpha- and then gamma-secretase proteolytic cleavage of p75, in a protein kinase C-dependent manner, and that this cleavage is necessary for both activation of Rho and inhibition of neurite outgrowth.


Assuntos
Glicoproteína Associada a Mielina/farmacologia , Inibição Neural/efeitos dos fármacos , Neuritos/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Receptores de Fator de Crescimento Neural/metabolismo , Secretases da Proteína Precursora do Amiloide , Animais , Animais Recém-Nascidos , Ácido Aspártico Endopeptidases/farmacologia , Western Blotting/métodos , Células Cultivadas , Cerebelo/citologia , Cricetinae , Cricetulus , Interações Medicamentosas , Endopeptidases , Ativação Enzimática/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Proteínas de Membrana/metabolismo , Neuritos/fisiologia , Neuroblastoma , Neurônios/fisiologia , Oligopeptídeos/farmacologia , Estrutura Terciária de Proteína/fisiologia , Ratos , Receptor de Fator de Crescimento Neural , Receptores de Fator de Crescimento Neural/química , Proteínas Recombinantes de Fusão/metabolismo , Proteínas Recombinantes de Fusão/farmacologia , Acetato de Tetradecanoilforbol/farmacologia , Transfecção/métodos , Proteínas rho de Ligação ao GTP/metabolismo
15.
Med Chem ; 1(1): 71-104, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16789888

RESUMO

This review describes the clinical status (based on available information) of experimental drugs that inhibit enzymes called proteases, or more precisely a sub-class of proteases called peptidases that catalyse the hydrolysis of polypeptide main chain amide bonds. These peptidases are classified by the key catalytic residue in the active site of the enzyme that effects hydrolysis, namely aspartic, serine, cysteine, metallo or threonine proteases. In this review we show structures for 108 inhibitors of these enzymes and update the clinical disposition of over 100 inhibitors that have been considered worthy enough by pharmaceutical, biotechnology or academic researchers and their financial backers to be trialed in humans as prospective medicines. We outline some of their chemical and pharmacological characteristics and compare the current status of protease inhibitors in the clinic with what was observed about 5 years ago (Leung et al, J. Med. Chem. 2000, 43, 305-341). We assess the progress of protease inhibitors into man, predict their futures, and outline some of the hurdles that have been overcome and that still remain for this promising class of new therapeutic agents.


Assuntos
Ensaios Clínicos como Assunto , Bases de Dados como Assunto , Inibidores de Proteases , Ácido Aspártico Endopeptidases/química , Ácido Aspártico Endopeptidases/farmacologia , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/farmacologia , Humanos , Estrutura Molecular , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Inibidores Teciduais de Metaloproteinases/química , Inibidores Teciduais de Metaloproteinases/farmacologia
16.
Br J Cancer ; 90(8): 1577-82, 2004 Apr 19.
Artigo em Inglês | MEDLINE | ID: mdl-15083188

RESUMO

Perturbations of stromal-epithelial interactions in the developing tumour can contribute to cancer invasion and metastasis. The structurally related metallopeptidases endothelin-converting enzyme (ECE) and neutral endopeptidase (NEP) contribute sequentially to the synthesis and inactivation of ET-1, a mitogenic peptide that has been shown to affect tumour behaviour. This study has investigated the interaction between metastatic tumour epithelial cells, which lack NEP, and stromal cells, which we have shown to express ECE-1 (stromal-epithelial interactions), using Matrigel invasion chambers. The epithelial cell lines utilised in this study include androgen-sensitive LNCaP, androgen-independent PC-3, Du145 and recently established PNT-1a, PNT2-C2 and P4E6 prostate cell lines. Specific inhibition of endogenous ECE-1 activity in stromal cells reduced PC-3 and Du145 invasion by 70 and 50%, respectively. Addition of recombinant NEP to inactivate endogenous mitogenic peptides resulted in 50 and 20% reductions in invasion in PC-3 and Du145 cells, respectively. Neutral endopeptidase effects were reversed in the presence of thiorphan, a specific NEP inhibitor. Supplementation of defined media with bradykinin and ET-1 significantly increased PC-3 invasion by 40 and 50%, respectively. Du145 cell invasion increased by approximately 100% on adding ET-1. These studies implicate the metallopeptidases NEP and ECE-1 as mediators of prostate cancer invasion via a stromal/epithelial interaction.


Assuntos
Ácido Aspártico Endopeptidases/farmacologia , Epitélio/fisiologia , Perfilação da Expressão Gênica , Invasividade Neoplásica/fisiopatologia , Neprilisina/farmacologia , Neoplasias da Próstata/patologia , Células Estromais/fisiologia , Ácido Aspártico Endopeptidases/genética , Comunicação Celular , Enzimas Conversoras de Endotelina , Humanos , Masculino , Metaloendopeptidases , Neprilisina/genética , Células Tumorais Cultivadas
17.
Prostaglandins Other Lipid Mediat ; 71(1-2): 55-73, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12749594

RESUMO

The objective of this experiment was to determine the effect of AA, LH, or PSPB on secretion of PGE2, PGF2alpha, or progesterone by ovine caruncular endometrium of the estrous cycle or placental tissue of pregnancy in vitro. Ovine caruncular endometrium of the estrous cycle (days 8, 11, 13, and 15) or caruncular/placental tissue on days 8, 11, 13, 15, 20, 30, 40, 50, 60, and 90 postbreeding were incubated in vitro with vehicle, AA, LH, or PSPB in M-199 for 4 and 8 h. Secretion of PGF2alpha by caruncular endometrium of non-bred ewes on days 13 and 15 and by caruncular/placental tissue of bred ewes on days 13, 15, 20, 30, and 40 was increased (P < or = 0.05) when incubated with vehicle and declined (P < or = 0.05) after day-40 in bred ewes. Secretion of PGF2alpha by day-15 caruncular endometrium of non-bred ewes and bred ewes was increased (P < or = 0.05) by AA on days 13 and 15 and by LH on day-15. Secretion of PGF2alpha by caruncular/placental tissue from bred ewes was (P < or = 0.05) by AA on days 13, 15, 20, 30, and 40 and by LH on days 15, 20, 30, and 40, after which the response decreased (P < or = 0.05). Secretion of PGF2alpha by caruncular endometrium of non-bred ewes during the estrous cycle or by caruncular/placental tissue of bred ewes during the first trimester was not affected by PSPB (P > or = 0.05). Secretion of PGE2 by caruncular endometrium of non-bred ewes did not change (P > or = 0.05) and was increased (P < or = 0.05) by caruncular/placental tissue on days 13-90 from bred ewes when incubated with vehicle. Secretion of PGE2 by endometrium from non-bred ewes was not affected (P > or = 0.05) by AA, LH, or PSPB, but was increased (P < or = 0.05) by AA or LH on days 13-50 and by PSPB on days 60 and 90 when incubated with caruncular/placental tissue from bred ewes. Secretion of progesterone by placental tissue of bred ewes increased (P < or = 0.05) on day-50 and continued to increase through day-90. In summary, uterine/placental tissue secretion of PGF2alpha is not reduced until the end of the first trimester of pregnancy in ewes. In addition, LH appears to play a role in luteolysis of non-bred ewes by stimulating caruncular endometrial secretion of PGF2alpha and on day-5 postbreeding to prevent luteolysis during early pregnancy by stimulating caruncular/placental secretion of PGE2 throughout the first trimester of pregnancy in sheep. Secretion of PGE2 by caruncular/placental tissue after day-50 of pregnancy appears to be regulated by PSPB, not LH.


Assuntos
Ácido Araquidônico/farmacologia , Ácido Aspártico Endopeptidases/farmacologia , Dinoprosta/metabolismo , Dinoprostona/metabolismo , Endométrio/efeitos dos fármacos , Hormônio Luteinizante/farmacologia , Placenta/efeitos dos fármacos , Proteínas da Gravidez/farmacologia , Progesterona/metabolismo , Animais , Ácido Aspártico Endopeptidases/fisiologia , Técnicas de Cultura , Dinoprosta/análise , Dinoprostona/análise , Endométrio/metabolismo , Estro , Feminino , Hormônio Luteinizante/fisiologia , Placenta/metabolismo , Gravidez , Proteínas da Gravidez/fisiologia , Progesterona/análise , Progesterona/sangue , Radioimunoensaio , Ovinos , Fatores de Tempo
18.
Arch Mal Coeur Vaiss ; 95(9): 821-6, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12407798

RESUMO

The angiotensin converting enzyme (ACE), endothelin (ET) converting enzyme (ECE) and neutral endopeptidase (NEP) are all zinc-metallopeptidases expressed in almost all the organs, such as heart, vessels and kidneys. While ACE and ECE are respectively involved in the transformation of angiotensin I and Big-ET into angiotensin II and ET-1 respectively, which possess vasoconstrictor and mitogenic properties, NEP is involved in the degradation of atrial natriuric factor (ANF), which possesses vasorelaxant, diuretic/natriuretic and antihypertrophic properties. These three systems are activated in heart failure and modulate the progression of heart failure. This article will discuss preliminary date concerning simultaneous inhibition of ACE, ECE and/or NEP and their therapeutic potential interest in the treatment of heart failure.


Assuntos
Inibidores da Enzima Conversora de Angiotensina/farmacologia , Ácido Aspártico Endopeptidases/farmacologia , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/fisiopatologia , Neprilisina/farmacologia , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Ácido Aspártico Endopeptidases/uso terapêutico , Progressão da Doença , Enzimas Conversoras de Endotelina , Humanos , Metaloendopeptidases/farmacologia , Metaloendopeptidases/uso terapêutico , Neprilisina/uso terapêutico
19.
Genome Biol ; 3(4): REVIEWS3006, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-11983066

RESUMO

SUMMARY: The proteases of retroviruses, such as leukemia viruses, immunodeficiency viruses (including the human immunodeficiency virus, HIV), infectious anemia viruses, and mammary tumor viruses, form a family with the proteases encoded by several retrotransposons in Drosophila and yeast and endogenous viral sequences in primates. Retroviral proteases are key enzymes in viral propagation and are initially synthesized with other viral proteins as polyprotein precursors that are subsequently cleaved by the viral protease activity at specific sites to produce mature, functional units. Active retroviral proteases are homodimers, with each dimer structurally related to the larger class of single-chain aspartic peptidases. Each monomer has four structural elements: two distinct hairpin loops, a wide loop containing the catalytic aspartic acid and an alpha helix. Retroviral gene sequences can vary between infected individuals, and mutations affecting the binding cleft of the protease or the substrate cleavage sites can alter the response of the virus to therapeutic drugs. The need to develop new drugs against HIV will continue to be, to a large extent, the driving force behind further characterization of retroviral proteases.


Assuntos
Endopeptidases , Retroviridae/enzimologia , Animais , Ácido Aspártico Endopeptidases/química , Ácido Aspártico Endopeptidases/genética , Ácido Aspártico Endopeptidases/farmacologia , Sítios de Ligação , Endopeptidases/química , Endopeptidases/genética , Endopeptidases/farmacologia , Evolução Molecular , Genes Virais , Protease de HIV/genética , Humanos , Modelos Moleculares , Mutação , Filogenia , Retroviridae/genética , Proteínas dos Retroviridae/química , Proteínas dos Retroviridae/genética , Proteínas dos Retroviridae/farmacologia
20.
Neurosci Lett ; 315(3): 145-8, 2001 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-11716984

RESUMO

The amyloid precursor protein (APP) undergoes two consecutive cleavages by different proteases, beta-secretase and gamma-secretase, leading to the release of an amyloidogenic 4 kDa fragment called amyloid beta (Abeta). Combining immunoprecipitation and mass spectrometry, we characterized soluble Abeta in cultured cell media of mouse neuroblastoma N2a cells and double hAPP/hBACE-1 transfected HEK293. The major Abeta isoforms detected were Abeta11-34, Abeta1-34, Abeta11-40 and Abeta1-40. In this study, we demonstrate that overexpression of human beta-secretase (BACE-1) in HEK293 cells resulted in predominant Abeta cleavage at position Glu(11) rather than Asp(1), as well as increased production of Abeta(x)-34, but not Abeta(x)-40. Incubation of cells with a specific gamma-secretase inhibitor suggests that cleavage of APP at Leu(34) could be mediated by gamma-secretase itself or by a gamma-secretase dependent process.


Assuntos
Peptídeos beta-Amiloides/biossíntese , Endopeptidases/fisiologia , Fragmentos de Peptídeos/biossíntese , Secretases da Proteína Precursora do Amiloide , Peptídeos beta-Amiloides/análise , Peptídeos beta-Amiloides/antagonistas & inibidores , Peptídeos beta-Amiloides/química , Precursor de Proteína beta-Amiloide/química , Precursor de Proteína beta-Amiloide/genética , Precursor de Proteína beta-Amiloide/metabolismo , Animais , Ácido Aspártico Endopeptidases/genética , Ácido Aspártico Endopeptidases/farmacologia , Linhagem Celular , Meios de Cultura/química , Endopeptidases/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Humanos , Camundongos , Fragmentos de Peptídeos/análise , Fragmentos de Peptídeos/antagonistas & inibidores , Isoformas de Proteínas/análise , Solubilidade , Transfecção
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA